de Mattos Ángelo Zambam, de Mattos Angelo Alves, Méndez-Sánchez Nahum
Post-Graduation Course of Hepatology of Federal University of Health Sciences of Porto Alegre, Brazil; Irmandade Santa Casa de Misericórdia de Porto Alegre Hospital, Brazil; Pontifical Catholic University of Rio Grande do Sul, Brazil.
Post-Graduation Course of Hepatology of Federal University of Health Sciences of Porto Alegre, Brazil; Irmandade Santa Casa de Misericórdia de Porto Alegre Hospital, Brazil.
Ann Hepatol. 2016 Jul-Aug;15(4):474-81.
Renal failure in cirrhotic patients is a very severe condition. Hepatorenal syndrome has the worst prognosis among all causes of kidney failure in such patients. Hepatorenal syndrome is diagnosed especially in cirrhotic patients with ascites who develop loss renal function, despite diuretic suspension and volume expansion with albumin and for whom other causes of kidney injury have been excluded. Patients with hepatorenal syndrome should be treated with a vasoconstrictor in combination with albumin as a bridge to receiving a liver transplant. The vasoconstrictor of choice is terlipressin or noradrenaline. In spite of higher drug-related costs associated to terlipressin, initial evidence demonstrates that, considering all direct medical costs involved, the treatment strategy using terlipressin is probably more economical than that using noradrenaline.
肝硬化患者的肾衰竭是一种非常严重的病症。肝肾综合征在这类患者肾衰竭的所有病因中预后最差。肝肾综合征尤其在伴有腹水的肝硬化患者中被诊断出来,这些患者出现肾功能丧失,尽管停用了利尿剂并使用白蛋白进行了扩容,且已排除其他肾损伤病因。肝肾综合征患者应使用血管收缩剂联合白蛋白进行治疗,作为接受肝移植的过渡。首选的血管收缩剂是特利加压素或去甲肾上腺素。尽管特利加压素的药物相关成本较高,但初步证据表明,考虑到所有涉及的直接医疗成本,使用特利加压素的治疗策略可能比使用去甲肾上腺素的策略更经济。